REFERENCES

  • www.who.int

  • www.wikipedia.org

  • www.rxlist.com

  • www.drugs.com

  • www.cvpharmacology.com

  • www.hypertensiononline.org

  • www.medicinenet.com

  • www.umm.edu

  • Prevention of Cardiovascular Disease: By Eugene A. DeFelice

  • Preventing Cardiovascular Disease in Primary Care By Clive Handler, Gerry Coghlan

  • Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry-by John H. Block John M. Beale, Jr.

  • Foye's principles of medicinal chemistry By William O. Foye, Thomas L. Lemke, David A. Williams

  • Pediatric Pharmacotherapy: A Monthly Review for Health Care Professionals of the Children's Medical Center- Volume 2, Number 6, June 1996

  • Journal of the American Academy of Pediatrics, Vol. 114 No. 1 July 2004, pp. 86-93, Allsands.com

  • Handbook of Experimental Pharmacology- Pharmacology and Therapeutics of Cough, by Kian Fan Chung and John Widdicombe

  • European Journal of Pediatrics, Volume 144, Number 6 / April, 1986

Broad Spectrum Antibiotics
  • Holden C. (1997). Antibiotic basis for spice use science 277:321

Breast Cancer
  1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards, BK (eds). SEER Cancer Statistics Review, 1973-1998, National Cancer Institute. Bethesda, MD. 2001

  2. Seralini G, Moslemi S: Aromatase inhibitors: past, present and future. Mol Cell Endocrino 2001: Jun 10;178(1-2):117-131.

  3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer.

  4. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998. 351:1451-1467.st cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; Sep;17(9):26

  5. Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med. Apr 3 2007;146(7):511-5.

  6. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. Mar-Apr 2007;57(2):75-89.
  7. Osteen R, Breast cancer. In Lenhard RE, OSTEEN RT,GlanslerT. Ads, clinical Oncology Atlanta. GA, a MWRICAN Cancer Society. 2001. 251-268.

  8. International Agency for cancer research.IARC Handbook for cancer prevention. Volume 6.

  9. Hortobagyi GN. Treatment of breast cancer. NEJM. 1998.339:974-984

  10. Henderson IC. Breast cancer. In: Murphy GP, Lawrence, Jr. WL, Lenhard, Jr. RE (eds). American Cancer Society Textbook of Clinical Oncology, 2nd ed. American Cancer Society. Atlanta, GA. 1995.

  11. Chau B, O livotto ia, Weir L, Kwin W, Truong P, Ragas J. Incresased use of adjuent regional therapy for node positive breast cancer in B ritish Colombia Breast J. 2004.

  12. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA-A Cancer Journal for Clinicians. 2001.

  13. Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet. 1995. 346:883-887.5-36.

  14. Kerlikowske K, Barclay J. Outcomes of modern screeningmammography. Monogr Natl Cancer Inst. 1997. 22:105-111.

  15. Complete Guide to Symptoms, Illness & Surgery By H. Winter Griffith, Stephen Moore, KENNETH YODER

  16. Atlas of procedures in breast cancer surgery. By Tari A. King, Patrick I. Borgen

  17. Managing side effects of chemotherapy and radiation therapy…. By Marylin J. Dodd ( 1 and 29)
  18. Current therapy in oncology . By John E. Niederhuber


  19. Breast cancer: the complete guide. By Yashar Hirshaut, Peter I. Pressman

Amoxicillin+Clavulanate Potassium for Oral Suspension USP-IN SACHETS
  1. Available at http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20A)/AMOXICILLIN.html Accessed on 17.3.09.

  2. Available at http://www.bmj.com/cgi/reprint/328/7443/791.pdf Accessed on 17.3.09.

  3. Oh HML, et al. Singapore med J. 1996;37:255-257.

  4. Bonadonna P, et al. J Invest Allergol Clin Immunol. 2005; 15(4): 302-304.

  5. Available at http://www.parpharm.com/pdf/product/amoxicillin298_po.pdf Accessed on 17.3.09.

  6. Woodnutt G, et al. Antimicrobial agents and chemotherapy. 1999;43(1):35-40

  7. Arrieta JR, et al. Am J Otolaryngol. 2007 Mar-Apr;28(2):78-82.

Ischemic Heart Disease
  1. World Health Organization Department of Health Statistics and Informatics in the Information, Evidence and Research Cluster (2004). The global burden of disease 2004 update. Geneva

  2. Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (2007). Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. pp. 345.

  3. Essentials of Medical Pharmacology- KD Tripathi, 5th Edition.

  4. Hypertension: management of hypertension in adults in primary care. Clinical guideline CG34. National Institute for Health and Clinical Excellence (NICE), June 2006.

  5. Law MR, Wald NJ, Rudnicka AR (June 2003). "Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis’’.

Calcium Channel Blockers
  1. Essentials of Medical Pharmacology- K.D Tripathi, 5th edition.

  2. Brown MJ, Palmer CR, Castaigne A, et al. (2000). "Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)". Lancet 356 (9227): 366–72.

  3. Poole-Wilson PA, Kirwan BA, Vokó Z, de Brouwer S, van Dalen FJ, Lubsen J (2006). "Safety of nifedipine GITS in stable angina: the ACTION trial".

  4. Hypertension: management of hypertension in adults in primary care. Clinical guideline CG34. National Institute for Health and Clinical Excellence (NICE), June 2006. .

  5. THE COMPLETE DRUG REFERENCE- Martindale, Thirty- fifth edition. .

Narrow Spectrum Antibiotics
  1. Oral and maxillofacial infection By Richard G. Topazian, Morton H. Goldberg, James R. Hupp

  2. Management of infections of the oral and maxillofacial regions By Richard G. Topazian, Morton H. Goldberg

  3. ESSENTIALS OF MEDICAL PHARMACOLOGY. K. D. TRIPATHI. Fifth edition.

  4. Infectious diseases By Sherwood L. Gorbach, John G. Bartlett, Neil R. Blacklow

  5. Drug facts and comparisons 2002 By Facts & Comparisons, Facts and Comparisons

Chemotherapy Drugs Against Breast Cancer
  1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 1998; 90(18):1371-1388.

  2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 2005; 97(22):1652-1662

  3. Fischer, David S; Knobf, M Tish; Durivage, Henry J; Beaulieu, Nancy J (2003). The Cancer Chemotherapy Handbook (6th Edition). Mosby. ISBN 0-323-01890-4

  4. Thomson Centerwatch: Drugs Approved by the FDA Xeloda) Retrieved 6/05

  5. M. F. S. A. Cerqueira, P. A. Fernandes, M. J. Ramos (2007). "Understanding ribonucleotide reductase inactivation by gemcitabine". Chemistry,a European Journal 13 (30)

  6. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008;100(1):14-20

  7. Essentials Of Medical Pharmacology By KD Tripathi.

  8. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H; (2005). "The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules";. Clin Immunol. 114 (Feb.): 154-163. doi:10.1016/j.clim.2004.09.001. PMID 15639649.

  9. "DOXIL Product Information." Ortho Biotech Products, L.P. Retrieved on April 19, 2007

  10. Johnson IS, Armstrong JG, Gorman M, Burnett JP (1 September 1963). "The vinca alkaloids: a new class of oncolytic agents". Cancer Res 23 (8 Part 1): 1390-427.

TripleTherapy For Helicobacter Pylori
  1. Mirbagheri SA, Hasibi M, Abouzari M, Rashidi A (August 2006). "tTriple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial". World J. Gastroenterol. 12 (30): 4888-91. Retrieved 2008-09-02.

  2. Malfertheiner P, Megraud F, O'Morain C, et al. (June 2007). "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report". Gut 56 (6): 772-81.

  3. Journal of Antimicrobial Chemotherapy (1995) 36, 1085-1088
    © 1995 The British Society for Antimicrobial Chemotherapy

Cefixime And Lactobacillus Combination
  1. Gut microflora: digestive physiology and pathology
    By Jean-Claude Rambaud, Jean-Paul Buts, Gérard Corthier, Bernard Flourie

  2. Oncology Nursing Drug Handbook
    By Gail M. Wilkes, Margaret Barton-Burke
Antineoplastic Agents / Anticancer Drugs
  1. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition.

  2. Essentials of Medical Pharmacology- K D Tripathi, 5th Edition
Hypercholesterolemia
  1. Statins: the HMG-CoA reductase inhibitors in perspective
    By Allan Gaw, Christopher J. Packard, James Shepherd

  2. Foye's principles of medicinal chemistry
    By David A. Williams, William O. Foye, Thomas L. Lemke

  3. Essentials Of Medical Pharmacology
    By KD Tripathi

  4. The Harvard Medical School guide to lowering your cholesterol
    By Mason W. Freeman, Christine E. Junge

Past Highlights

top
HOME   ABOUT US   PRODUCTS   QUALITY & COMPLIANCE   MANUFACTURING   GROUP OF COMPANIES  
HIGHLIGHTS   NEWS & EVENTS   CAREER   DOWNLOADS   CONTACT US   SITEMAP   REFERENCES   GLOSSARY  
Copyright © 1995-2009 SRS PHARMACEUTICALS PVT. LTD. Designed and Developed by Miracleworx Web Design India